Genomic Medicine
Genomic research, the future of health
Through our subsidiary Landsteiner Genmed, a biopharmaceutical company, we focus on the discovery and development of genomic medicine for the treatment of diseases that affect human health.
The pillars of the research are based on genomic knowledge, which, together with our experience in the development of medicines, a team of high-level scientists and the support of allies in conducting preclinical tests in vitro et in vivo, we work to obtain pioneering medications in its class targeting diseases that lack of appropriate drug treatment.
Landsteiner GenMed has intellectual property (patents) in protocols for obesity, Alzheimer’s, heart disease, cancer, among others. Learn more about them:
Antihypertensive (High blood pressure)
- The advantage is the jointly administration of 3 drugs, but of sequential effect.
- Patent granted in Mexico and Japan.
- Patent in process of being granted in United States and the European Union.
Obesity control
- Advantages: administration of hypoglycemic with reversible inhibitor of the gastric and pancreatic lipase in the whole intestine.
Osteoporosis
- The advantage the formulation offers is that it counts with an improved stability.
- Patent granted in Mexico and European Union.
- Patent in process of being granted in United States and Japan.
Rheumatoid, psoriatic arthritis or ankylosing spondylitis
- The main advantage is offering a formulation that has an improved shelf stability proven with stability test.
- Patent in process of being granted in Mexico.
Triglyceride control
- It contains new chemical compounds (API’s) Patent granted in the European Union
- Patent in process of evaluation in Mexico, United States, Japan, Canada, Peru, Australia, Colombia, Eurasian Patent Office, Ukraine, Costa Rica, and Republic of Korea
Landsteiner GenMed Pipeline
All rights reserved. Landsteiner 2024® | COFEPRIS | Do not self-medicate. Consult your physician for additional information.